Asked by: Sureena Brackenridge (Labour - Wolverhampton North East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential impact of the Mental Health Bill on mental wellbeing in Wolverhampton.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We have carried out an Impact Assessment, which is in the public domain and is available on the Bills Parliament web page. The benefits related to wellbeing in the Impact Assessment are not quantified but are explored through breakeven analysis. The analysis seeks to estimate the non-monetised benefits required to offset the estimated net monetised impacts of the policy.
The bill largely follows the recommendations of the Independent Review of the Mental Health Act, which heard from a broad range of stakeholders and views, including service users and carers, to make recommendations to improve people’s experience of the Mental Health Act.
Asked by: Sureena Brackenridge (Labour - Wolverhampton North East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of funding for charitable hospices.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
We want a society where every person receives high-quality, compassionate care from diagnosis through to the end of life. This government is determined to shift more healthcare out of hospitals and into the community, to ensure patients and their families receive personalised care in the most appropriate setting and hospices will have a big role to play in that shift.
Most hospices are charitable, independent organisations which receive some statutory funding from the National Health Service. The amount of funding charitable hospices receive varies by integrated care board (ICB) area, and will, in part, be dependent on the local population need and a system-wide approach using a range of palliative and end of life care provision within their ICB footprint.
I recently met NHS England and discussions have begun on how to reduce inequalities and variation in access to, and the quality of, palliative and end of life care. We will consider next steps on palliative and end of life care, including funding, in the coming months.
Additionally, we have committed to develop a 10-year plan to deliver a NHS fit for the future, by driving three shifts in the way health care is delivered. We will carefully be considering policies, including those that impact people with palliative and end of life care needs, with input from the public, patients, health staff and our stakeholders as we develop the plan.
More information about how members of the public, patients, healthcare staff and stakeholder organisations can input into the 10-Year Health Plan is available at the following link:
Asked by: Sureena Brackenridge (Labour - Wolverhampton North East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help tackle drug shortages.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has a responsibility to work with United Kingdom medicine license holders, to help ensure continuity of supply. We monitor and manage medicine supply at a national level, so that stocks remain available to meet regional and local demand.
We have inherited ongoing global supply problems that continue to impact medicine availability. We know how frustrating and distressing this can be for patients, and we are working closely with industry, the National Health Service, manufacturers, and other partners in the supply chain to resolve these issues as quickly as possible, to make sure patients can access the medicines they need.
Medicine supply chains are complex, global, and highly regulated, and there are a number of reasons why supply can be disrupted, many of which are not specific to the UK and outside of the Government’s control, including manufacturing difficulties, access to raw materials, sudden demand spikes or distribution issues, and regulatory issues. There are approximately 14,000 licensed medicines, and the overwhelming majority are in good supply.
While we cannot always prevent supply issues from occurring, we have a range of well-established processes and tools to manage them when they arise, and to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing NHS communications to provide management advice and information on the issue to healthcare professionals, including pharmacists, so they can advise and support their patients.